Exploring the Potential of MicroRNA Let-7c As a Therapeutic for Prostate Cancer

Overview

Journal Mol Ther Nucleic Acids

Publisher Cell Press

Date 2019 Nov 25

PMID 31760377

Citations 10

Authors

Eoghan J Mulholland

William P Green

Niamh E Buckley

Helen O McCarthy

Affiliations

Soon will be listed here.

Abstract

Prostate cancer (PCa) is one of the leading causes of mortality worldwide and often presents with aberrant microRNA (miRNA) expression. Identifying and understanding the unique expression profiles could aid in the detection and treatment of this disease. This review aims to identify miRNAs as potential therapeutic targets for PCa. Three bio-informatic searches were conducted to identify miRNAs that are reportedly implicated in the pathogenesis of PCa. Only hsa-Lethal-7 (let-7c), recognized for its role in PCa pathogenesis, was common to all three databases. Three further database searches were conducted to identify known targets of hsa-let-7c. Four targets were identified, HMGA2, c-Myc (MYC), TRAIL, and CASP3. An extensive review of the literature was undertaken to assess the role of hsa-let-7c in the progression of other malignancies and to evaluate its potential as a therapeutic target for PCa. The heterogeneous nature of cancer makes it logical to develop mechanisms by which the treatment of malignancies is tailored to an individual, harnessing specific knowledge of the underlying biology of the disease. Resetting cellular miRNA levels is an exciting prospect that will allow this ambition to be realized.

Citing Articles

miRNAs Dysregulated in Human Papillomavirus-Associated Benign Prostatic Lesions and Prostate Cancer.

Salgado-Hernandez S, Martinez-Retamoza L, Ocadiz-Delgado R, Perez-Mora S, Cedeno-Arboleda G, Gomez-Garcia M Cancers (Basel). 2025; 17(1.

PMID: 39796656 PMC: 11718816. DOI: 10.3390/cancers17010026.

Decoding high mobility group A2 protein expression regulation and implications in human cancers.

Khazem F, Zetoune A Discov Oncol. 2024; 15(1):322.

PMID: 39085703 PMC: 11291832. DOI: 10.1007/s12672-024-01202-x.

A study of microRNAs as new prognostic biomarkers in anal cancer patients.

Dahl O, Myklebust M Acta Oncol. 2024; 63:456-465.

PMID: 38899393 PMC: 11332526. DOI: 10.2340/1651-226X.2024.27976.

Cross Talk between MicroRNAs and Dengue Virus.

Macha N, Komarasamy T, Harun S, Adnan N, Hassan S, Balasubramaniam V Am J Trop Med Hyg. 2024; 110(5):856-867.

PMID: 38579704 PMC: 11066346. DOI: 10.4269/ajtmh.23-0546.

PSMC2 promotes the progression of gastric cancer via induction of RPS15A/mTOR pathway.

Liu T, Zhang J, Chen H, Bianba T, Pan Y, Wang X Oncogenesis. 2022; 11(1):12.

PMID: 35256584 PMC: 8901802. DOI: 10.1038/s41389-022-00386-7.

References

Winter R, Kramer A, Borkowski A, Kyprianou N . Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res. 2001; 61(3):1227-32. View

Roush S, Slack F . The let-7 family of microRNAs. Trends Cell Biol. 2008; 18(10):505-16. DOI: 10.1016/j.tcb.2008.07.007. View

Du W, Hong L, Yao T, Yang X, He Q, Yang B . Synthesis and evaluation of water-soluble docetaxel prodrugs-docetaxel esters of malic acid. Bioorg Med Chem. 2007; 15(18):6323-30. DOI: 10.1016/j.bmc.2007.04.002. View

Zhang W, Le T, Liu L, Zhou Z, Li J . Predicting miRNA Targets by Integrating Gene Regulatory Knowledge with Expression Profiles. PLoS One. 2016; 11(4):e0152860. PMC: 4827848. DOI: 10.1371/journal.pone.0152860. View

Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H . The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011; 17(2):211-5. PMC: 3076220. DOI: 10.1038/nm.2284. View

Ekimler S, Sahin K . Computational Methods for MicroRNA Target Prediction. Genes (Basel). 2014; 5(3):671-83. PMC: 4198924. DOI: 10.3390/genes5030671. View

Oskarsson T, Batlle E, Massague J . Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell. 2014; 14(3):306-21. PMC: 3998185. DOI: 10.1016/j.stem.2014.02.002. View

Wang M, Ren D, Guo W, Wang Z, Huang S, Du H . Loss of miR-100 enhances migration, invasion, epithelial-mesenchymal transition and stemness properties in prostate cancer cells through targeting Argonaute 2. Int J Oncol. 2014; 45(1):362-72. DOI: 10.3892/ijo.2014.2413. View

Jalava S, Urbanucci A, Latonen L, Waltering K, Sahu B, Janne O . Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene. 2012; 31(41):4460-71. DOI: 10.1038/onc.2011.624. View

10.

Lozier A, Rich M, Grawe A, Peck A, Zhao P, Chang A . Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma. Oncotarget. 2014; 6(1):196-206. PMC: 4381588. DOI: 10.18632/oncotarget.2768. View

11.

Anees M, Horak P, El-Gazzar A, Susani M, Heinze G, Perco P . Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. Cancer. 2011; 117(6):1172-82. DOI: 10.1002/cncr.25504. View

12.

Williams L, Veliceasa D, Vinokour E, Volpert O . miR-200b inhibits prostate cancer EMT, growth and metastasis. PLoS One. 2014; 8(12):e83991. PMC: 3877136. DOI: 10.1371/journal.pone.0083991. View

13.

Tong S, Liu J, Wang X, Qu L . microRNA-181 promotes prostate cancer cell proliferation by regulating DAX-1 expression. Exp Ther Med. 2014; 8(4):1296-1300. PMC: 4151665. DOI: 10.3892/etm.2014.1846. View

14.

Wilson J . Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab. 2009; 96(4):151-7. DOI: 10.1016/j.ymgme.2008.12.016. View

15.

Chang T, Zeitels L, Hwang H, Chivukula R, Wentzel E, Dews M . Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A. 2009; 106(9):3384-9. PMC: 2651245. DOI: 10.1073/pnas.0808300106. View

16.

Honeywell D, Cabrita M, Zhao H, Dimitroulakos J, Addison C . miR-105 inhibits prostate tumour growth by suppressing CDK6 levels. PLoS One. 2013; 8(8):e70515. PMC: 3737265. DOI: 10.1371/journal.pone.0070515. View

17.

Ueno K, Hirata H, Shahryari V, Deng G, Tanaka Y, Tabatabai Z . microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer. Br J Cancer. 2013; 108(8):1659-67. PMC: 3668476. DOI: 10.1038/bjc.2013.125. View

18.

Schaefer A, Jung M, Mollenkopf H, Wagner I, Stephan C, Jentzmik F . Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2009; 126(5):1166-76. DOI: 10.1002/ijc.24827. View

19.

Khanmi K, Ignacimuthu S, Paulraj M . MicroRNA in prostate cancer. Clin Chim Acta. 2015; 451(Pt B):154-60. DOI: 10.1016/j.cca.2015.09.022. View

20.

Park S, Shell S, Radjabi A, Schickel R, Feig C, Boyerinas B . Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle. 2007; 6(21):2585-90. DOI: 10.4161/cc.6.21.4845. View